21st Annual NATA Symposium
The 21st Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place on April 23-24, 2020 in Athens, Greece.
Please click on the link below for more information
21st Annual Symposium General Information
Follow NATA on LinkedIn and Twitter
Join NATA's group on LinkedIn and follow NATA on Twitter (@NATAforum) to receive the latest news on patient blood management, haemostasis and thrombosis, and to participate in discussions with colleagues in the field.
LinkedIn Group / Twitter
News from the Industry
New clinical data support efficacy of fibrinogen concentrate (fibryga®) in treating acquired fibrinogen deficiency and lead to label extension in Europe
Fibrinogen replacement is widely accepted as an approach to managing acquired fibrinogen deficiency (AFD) in patients with critical bleeding, despite a lack of evidence until now from controlled clinical studies. Data from two comparative studies with Octapharma's highly-purified, dual pathogen-inactivated fibrinogen concentrate fibryga® have recently been published, and provide robust clinical support for this treatment approach.
The outcomes of a randomised, controlled clinical trial investigating approaches to bleeding control during cytoreductive surgery in 55 patients with pseudomyxoma peritonei were presented at the ISTH 2019 Congress in July. Fibrinogen replacement was effective for treatment of AFD in all cases, as measured by overall haemostatic efficacy. The results demonstrated non-inferiority of fibryga® (n = 22) compared with cryoprecipitate (n = 23) (p < 0.0095 for non-inferiority).
More recently, data from the first large multicentre, randomised controlled trial in AFD were published (JAMA, 2019). In a study of 827 patients undergoing cardiac surgery, fibryga® met the non-inferiority endpoint compared with cryoprecipitate (p < 0.001 for non-inferiority). Safety profiles of fibryga® and cryoprecipitate were comparable. Based on these clinical data, fibryga® received approval in the European Union for treatment of acquired fibrinogen deficiencies.
Read more at www.fibrinogendeficiency.com.
Patient Blood Management is not about blood transfusion: it is about patients' outcomes
"We can only agree with some of the recommendations put forward by the 2018 Frankfurt Consensus Conference, the authors write, but we feel that a true consensus between blood bankers, clinicians well-versed in the management of patients undergoing major surgery at risk of bleeding and researchers in the field would have sent a stronger and more relevant message in favour of PBM."
"PBM is not an offensive against producers of blood components. PBM aims to improve the outcomes of patients at risk through the optimisation of the patient's condition before, during and after the procedure."
Read more on this
Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement
The aim of this multidisciplinary consensus statement, published online ahead of print in Blood Transfusion on February 6, 2019, is to provide recommendations on the prevention and treatment of postpartum haemorrhage as part of patient blood management in obstetrics.
It was developed by NATA in collaboration with the International Federation of Gynaecology and Obstetrics (FIGO), the European Board and College of Obstetrics and Gynaecology (EBCOG) and the European Society of Anaesthesiology (ESA).
Read more on this